Pharmacokinetic Evaluations of the Co-Administrations of Vandetanib and Metformin, Digoxin, Midazolam, Omeprazole or Ranitidine

Johansson, Susanne; Read, Jessica; Oliver, Stuart; Steinberg, Mark L.; Li, Yan; Lisbon, Eleanor; Mathews, David; Leese, Philip T.; Martín, Paul

doi:10.1007/s40262-014-0161-2

Cited by 53 publications

(30 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vandetanib, an OCT substrate, is a selective inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor. Coadministration of vandetanib and metformin demonstrated that C max and AUC values of metformin increased by 74% and 50%, respectively, and its renal clearance decreased by 52% (Johansson et al, 2014). In addition, hepatocyte uptake of metformin via OCT1 is strongly inhibited by verapamil; as a result, glucose-lowering effect of metformin is decreased (Cho et al, 2014).…”

Section: Adverse Reactionsmentioning

confidence: 99%

Microparticulate and nanoparticulate drug delivery systems for metformin hydrochloride

Çetin

Şahin

2015

Drug Delivery

View full text Add to dashboard Cite

Context: Metformin hydrochloride is a biguanide derivative widely used for the treatment of type 2 diabetes, prescribed nearly to 120 million people worldwide. Metformin has a relatively low oral bioavailability (about 50-60%). Although the major effect of metformin is to decrease hepatic glucose output as an antihyperglycemic agent, its inhibitory effects on the proliferation of some cancer cells (e.g. prostate, breast, glioma cells) have been demonstrated in the cell culture studies. Development of novel formulation (e.g. microparticles, nanoparticles) strategies for metformin might be useful to improve its bioavailability, to reduce the dosing frequency, to decrease gastrointestinal side effects and toxicity and to be helpful for effective use of metformin in cancer treatment. Objective: The main aim of this review is to summarize metformin HCl-loaded micro-and nanoparticulate drug delivery systems. Method: The literature was rewieved with regard to the physicochemical, pharmacological properties of metformin, and also its mechanism of action in type 2 diabetes and cancer. In addition, micro-and nanoparticulate drug delivery systems developed for metformin were gathered from the literature and the results were discussed. Conclusion: Metformin is an oral antihyperglycemic agent and also has potential antitumorigenic effects. The repeated applications of high doses of metformin (as immediate release formulations) are needed for an effective treatment due to its low oral bioavailability and short biological half-life. Drug delivery systems are very useful systems to overcome the difficulties associated with conventional dosage forms of metformin and also for its effective use in cancer treatment.

show abstract

Section: Adverse Reactionsmentioning

confidence: 99%

Microparticulate and nanoparticulate drug delivery systems for metformin hydrochloride

Çetin

Şahin

2015

Drug Delivery

View full text Add to dashboard Cite

show abstract

“…Midazolam can exhibit its effects immediately after intravenous administration and has the strongest effect 3 min later. Its distribution half-life after a single intravenous injection is 0.31 ± 0.24 h [22] . In this study, the effect of midazolam on mother and fetus was observed within its half-life period.…”

Section: Discussionmentioning

confidence: 99%

Influences of Different Doses of Midazolam on Mother and Fetus in Fetoscopic Surgery for Twin-to-Twin Transfusion Syndrome

Han

Tian

et al. 2015

Pharmacology

View full text Add to dashboard Cite

Objective: We observed influences of different doses of intravenous midazolam on mother and fetus in fetoscopic surgery for twin-to-twin transfusion syndrome (TTTS). Methods: A total of 18 pregnant women with TTTS were randomly divided into groups M1 and M2 according to differing doses of midazolam. Some parameters were respectively recorded as prior to administration of midazolam (T0), instantly after anesthesia induction (T1), at incision (T2), instantly after laser coagulation (T3) and at the end of surgery (T4). Results: There was no statistical difference in oxygen saturation and respiratory rate between groups M1 and M2 (all p > 0.05); but mean arterial pressure, heart rate, anxiety visual analog test, Observer's Assessment of Alertness/Sedation scale values and Kreb's scores were significantly lower in group M2 than in group M1 from T1 to T4 (all p < 0.05). In both groups, there was no fetal movement during laser coagulation. Conclusion: We propose that the appropriate dose for midazolam be 0.02 mg/kg in fetoscopic surgery for TTTS.

show abstract

“…16,[18][19][20] Reactions were seen in 88% of treated vs 23% of placebo-controlled patients and most were CTCAE grade 1 or 2. However 7% of treated patients had grade 3 reactions.…”

Section: Skin Reactionsmentioning

confidence: 99%

The safety of vandetanib for the treatment of thyroid cancer

Tsang

Robinson

Learoyd

2016

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

show abstract

Pharmacokinetic Evaluations of the Co-Administrations of Vandetanib and Metformin, Digoxin, Midazolam, Omeprazole or Ranitidine

Abstract: Patients receiving vandetanib with metformin/digoxin may require additional monitoring of metformin/digoxin, with dose adjustments where necessary. Vandetanib with CYP3A4 substrates or omeprazole/ranitidine is unlikely to result in clinically relevant drug-drug interactions.

Cited by 53 publications

References 20 publications

Microparticulate and nanoparticulate drug delivery systems for metformin hydrochloride

Microparticulate and nanoparticulate drug delivery systems for metformin hydrochloride

Influences of Different Doses of Midazolam on Mother and Fetus in Fetoscopic Surgery for Twin-to-Twin Transfusion Syndrome

The safety of vandetanib for the treatment of thyroid cancer

Contact Info

Product

Resources

About